CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer

被引：0
|
作者：
Sam Z. Thalji
Mandana Kamgar
Ben George
Mohammed Aldakkak
Kathleen K. Christians
Callisia N. Clarke
Beth A. Erickson
William A. Hall
Parag P. Tolat
Zachary L. Smith
Douglas B. Evans
Susan Tsai
机构：
[1] Medical College of Wisconsin,Department of Surgery, Division of Surgical Oncology, LaBahn Pancreatic Cancer Program
[2] Medical College of Wisconsin,Department of Medicine, Division of Medical Oncology, LaBahn Pancreatic Cancer Program
[3] Medical College of Wisconsin,Department of Radiation Oncology, LaBahn Pancreatic Cancer Program
[4] Medical College of Wisconsin,Department of Radiology, LaBahn Pancreatic Cancer Program
[5] Medical College of Wisconsin,Department of Medicine, Division of Gastroenterology and Hepatology, LaBahn Pancreatic Cancer Program
来源：
Annals of Surgical Oncology | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3013 / 3021
页数：8
相关论文
共 50 条
  • [1] CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer
    Thalji, Sam Z.
    Kamgar, Mandana
    George, Ben
    Aldakkak, Mohammed
    Christians, Kathleen K.
    Clarke, Callisia N.
    Erickson, Beth A.
    Hall, William A.
    Tolat, Parag P.
    Smith, Zachary L.
    Evans, Douglas B.
    Tsai, Susan
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (05) : 3013 - 3021
  • [2] ASO Visual Abstract: CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/ nab-Paclitaxel for Patients with Operable Pancreatic Cancer
    Sam Z. Thalji
    Mandana Kamgar
    Ben George
    Mohammed Aldakkak
    Kathleen K. Christians
    Callisia N. Clarke
    Beth A. Erickson
    William A. Hall
    Parag P. Tolat
    Zachary L. Smith
    Douglas B. Evans
    Susan Tsai
    Annals of Surgical Oncology, 2023, 30 : 3022 - 3022
  • [3] ASO Visual Abstract: CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/nab-Paclitaxel for Patients with Operable Pancreatic Cancer
    Thalji, Sam Z.
    Kamgar, Mandana
    George, Ben
    Aldakkak, Mohammed
    Christians, Kathleen K.
    Clarke, Callisia N.
    Erickson, Beth A.
    Hall, William A.
    Tolat, Parag P.
    Smith, Zachary L.
    Evans, Douglas B.
    Tsai, Susan
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (5) : 3022 - 3022
  • [4] Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
    Mita, Naoki
    Iwashita, Takuji
    Uemura, Shinya
    Yoshida, Kensaku
    Iwasa, Yuhei
    Ando, Nobuhiro
    Iwata, Keisuke
    Okuno, Mitsuru
    Mukai, Tsuyoshi
    Shimizu, Masahito
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [5] Second-line treatment with modified FOLFIRINOX in patients with pancreatic adenocarcinoma who have failed first-line treatment with gemcitabine and nab-paclitaxel
    McSweeney, T.
    Das, A.
    O'Mahony, A.
    O'Tighearnaigh, F.
    O'Byrne, L.
    Feely, M.
    Passmore, E.
    Keane, S.
    Lanigan, S.
    Fitzgerald, S.
    Browne, T.
    De Beer, V.
    Dean, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S133 - S133
  • [6] NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
    Nichetti, Federico
    Rota, Simone
    Ambrosini, Paolo
    Pircher, Chiara
    Gusmaroli, Eleonora
    Busset, Michele Droz Dit
    Pusceddu, Sara
    Sposito, Carlo
    Coppa, Jorgelina
    Morano, Federica
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    Mariani, Luigi
    Mazzaferro, Vincenzo
    de Braud, Filippo
    Niger, Monica
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [7] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [8] Modified FOLFIRINOX as second-line therapy in 140 patients with pancreatic adenocarcinoma patients who have failed first-line treatment using gemcitabine and nab-paclitaxel
    Farrell, D.
    Fitzgerald, S.
    Daly, A.
    Knox, B.
    Divilly, J.
    Robinson, M.
    Gallagher, L.
    Burke, P.
    Dean, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S148 - S148
  • [9] Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel
    Riedl, Jakob M.
    Schwarzenbacher, Esther
    Moik, Florian
    Horvath, Lena
    Gantschnigg, Antonia
    Renneberg, Felix
    Posch, Florian
    Barth, Dominik A.
    Stotz, Michael
    Pichler, Martin
    Hatzl, Stefan
    Fandler-Hofler, Simon
    Gressenberger, Paul
    Gary, Thomas
    Jost, Philipp J.
    Greil, Richard
    Ay, Cihan
    Djanani, Angela
    Gerger, Armin
    Schlick, Konstantin
    THROMBOSIS AND HAEMOSTASIS, 2022, 122 (04) : 633 - 645
  • [10] Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
    Ozaka, Masato
    Sasaki, Takashi
    Yamada, Ikuhiro
    Kanata, Ryo
    Akiyama, Dai
    Katagiri, Tomoko
    Takano, Koichi
    Matsuyama, Masato
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345